PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend · last filed 2026-03-20
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2023-03-31 was $0.00.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2022-03-31 was $0.00.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2025 was $0.00.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2024 was $0.00.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2023 was $0.00.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2022 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-20 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-20 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |